In the United States, bladder cancer is the sixth most common cancer. When cancer is confined to the tissue lining the inner surface of the bladder and has not invaded the bladder's muscle layer, it is classified as non-muscle-invasive bladder cancer (NMIBC). It represents about 80% of all bladder cancer cases and is associated with a high recurrence rate of approximately 50 to 80% over five years. Johnson & Johnson's INLEXZO and Urogen's ZUSDURI are some of the approved drugs for non-muscle-invasive bladder cancer.
The company we are profiling today is Relmada Therapeutics Inc. (RLMD), which is developing a drug for non-muscle invasive bladder cancer.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com